Alydia Health, Inc.

Alydia Health, Inc. specializes in innovative medical solutions, focusing on the treatment of postpartum hemorrhage through its flagship product, the JADA® System, enhancing care for women during critical health situations. Alydia Health, Inc. was founded in 2011 in Menlo Park, US, and is dedicated to addressing abnormal postpartum bleeding.

The company has undergone strategic pivots in its operations, focusing primarily on obstetric care. It was founded by Brandon Simonds and Jessie Becker. In March 2021, Alydia Health was the target of a Trade Sale to Merck & Co. , Inc.

for USD 240. 00 mn, consolidating its resources and expertise into a larger healthcare framework. The total amount raised by the company stands at USD 240. 00 mn through this latest funding round.

The JADA® System is Alydia Health's core product designed for the control and treatment of abnormal postpartum uterine bleeding. By utilizing low-level vacuum pressure, this system induces physiological contractions of the uterus, rapidly controlling bleeding in emergency situations. The JADA® System is currently utilized in over 2,000 hospitals across the United States, catering to healthcare professionals who require effective management of postpartum conditions, primarily targeting hospitals and clinicians focused on women's health. Alydia Health's revenue is derived from direct sales of the JADA® System to hospitals and healthcare providers, emphasizing a B2B transaction model.

The specifics of pricing are not disclosed; however, the system is recognized as a vital medical device in emergency obstetric care. The company also forms partnerships with healthcare organizations to enhance the distribution of its technology, ensuring a steady revenue stream aligned with the demands of providing advanced care in obstetrics. Following the March 2021 acquisition agreement with Merck & Co. , Inc.

, Alydia Health is positioned for strategic growth. The firm anticipates refining its product offerings and plans to leverage the acquisition to expand into new markets. The completion of the spinoff from Merck is expected in late Q2 2021, which will facilitate the enhancement of its product lines and market reach.